Abstract
In spite of the significant advances made in the conventional treatment modalities currently available for the treatment of lung cancer, this malignancy remains the most frequent cause of cancer death in North America. In recent years, therefore, much attention has been given to identify noncross-resistant modalities of treatment that could potentially be used as an adjunct in the therapy of lung cancer. Recently there has been increasing optimism that gene therapy may be utilized as an approach to develop these novel anti-cancer treatment modalities. The field of gene therapy is still in its infancy with no major successes being reported yet in the treatment of cancer patients. However the limited positive results that have been reported have demonstrated the possibilities of this approach. With regard to the treatment of cancer patients, there are four main strategies that have been devised. These include the introduction of suicide genes, the replacement of defective tumor-suppressor genes, the inactivation of oncogenes, and immunotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albelda, S. M., Wiewrodt, R., and Zuckerman, J. B. (2000) Gene therapy for lung disease: hype or hope? Ann. Intern. Med. 132, 649ā660.
Blaese, R. M., Ishii-Morita, H., Mullen, C., Ramsey, J., Ram, Z., Oldfield, E., and Culver, K. (1994) In situ delivery of suicide genes for cancer treatment. Eur. J. Cancer 8, 1190ā1193.
Mullen, C. A. (1994) Metabolic suicide genes in gene therapy. Pharmacol. Ther. 63, 199ā207.
Singhal, S. and Kaiser, L. R. (1998) Cancer chemotherapy using suicide genes. Surg. Oncol. Clin. North Am. 7, 505ā536.
Reid, R., Mar, E. C., Huang, E. S., and Topal, M. D. (1988) Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J. Biol. Chem. 263, 3898ā3904.
Gane, E., Saliba, F., Valdecasas, G. J., OāGrady, J., Pescovitz, M. D., Lyman, S., and Robinson, C. A. (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected] [see comments] [published erratum appears in Lancet 1998 Feb 7;351(9100):454]. Lancet 350, 1729ā1733.
Freeman, S. M., Whartenby, K. A., Freeman, J. L., Abboud, C. N., and Marrogi, A. J. (1996) In situ use of suicide genes for cancer therapy. Semin. Oncol. 23, 31ā45.
Pope, I. M., Poston, G. J., and Kinsella, A. R. (1997) The role of the bystander effect in suicide gene therapy. Eur. J. Cancer 33, 1005ā1016.
Rubsam, L. Z., Boucher, P. D., Murphy, P. J., KuKuruga, M., and Shewach, D. S. (1999) Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 59, 669ā675.
Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., et al. (1998) Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Human Gene Ther. 9, 1083ā1092.
(1999) Human gene marker/ therapy clinical protocols (complete updated listings). Human Gene Ther. 10, 2037ā2088.
Nemunaitis, J. (1999) Oncolytic viruses. Invest. New Drugs 17, 375ā386.
You, L., Yang, C. T., and Jablons, D. M. (2000) ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res. 60, 1009ā1013.
Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., et al. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359ā6366.
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., et al. (1989) p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491ā494.
Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323ā331.
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., et al. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer [see comments]. Nat. Med. 2, 985ā991.
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., et al. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91, 763ā771.
Roth, J. A., Swisher, S. G., Merritt, J. A., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., et al. (1998) Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol. 25, 33ā37.
Inoue, A., Narumi, K., Matsubara, N., Sugawara, S., Saijo, Y., Satoh, K., and Nukiwa, T. (2000) Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett. 157, 105ā112.
Nemunaitis, J., Swisher, S. G., Timmons, T., Connors, D., Mack, M., Doerksen, L., et al. (2000) Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18, 609ā622.
Schuler, M., Rochlitz, C., Horowitz, J. A., Schlegel, J., Perruchoud, A. P., Kom-moss, F., et al. (1998) A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Human Gene Ther. 9, 2075ā2082.
Kubba, S., Adak, S., Schiller, J., Slovis, B., Coffee, K., Worrel, J., et al. (2000) Phase I trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage. Proc. Am. Soc. Clin. Oncol. Abstract #1904.
Xu, M., Kumar, D., Srinivas, S., Detolla, L. J., Yu, S. F., Stass, S. A., and Mixson, A. J. (1997) Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Human Gene Ther. 8, 177ā185.
Bouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., et al. (1998) Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58, 2288ā2292.
Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T., et al. (1999) Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin. Cancer Res. 5, 1015ā1023.
Watanabe, T. and Sullenger, B. A. (2000) Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc. Natl. Acad. Sci. USA 97, 8490ā8494.
Parr, M. J., Manome, Y., Tanaka, T., Wen, P., Kufe, D. W., Kaelin, W. G., and Fine, H. A. (1997) Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 3, 1145ā1149.
Strayer, M. S., Guttentag, S. H., and Ballard, P. L. (1998) Targeting type II and Clara cells for adenovirus-mediated gene transfer using the surfactant protein B promoter. Am. J. Respir. Cell Mol. Biol. 18, 1ā11.
Salgia, R. and Skarin, A. T. (1998) Molecular abnormalities in lung cancer. J. Clin. Oncol. 16, 1207ā1217.
Kawabe, S., Roth, J. A., Wilson, D. R., and Meyn, R. E. (2000) Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene 19, 5359ā5366.
Naruse, I., Hoshino, H., Dobashi, K., Minato, K., Saito, R., and Mori, M. (2000) Over-expression of p27kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int. J. Cancer 88, 377ā383.
Ishizaki, J., Nevins, J. R., and Sullenger, B. A. (1996) Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nat. Med. 2, 1386ā1389.
Haber, D. A. and Fearon, E. R. (1998) The promise of cancer genetics. Lancet 351(Suppl. 2), SII1ā8.
Stass, S. A. and Mixson, J. (1997) Oncogenes and tumor suppressor genes: therapeutic implications. Clin. Cancer Res. 3, 2687ā2695.
Tanner, N. K. (1999) Ribozymes: the characteristics and properties of catalytic RNAs. FEMS Microbiol. Rev. 23, 257ā275.
Arndt, G. M. and Rank, G. H. (1997) Colocalization of antisense RNAs and ribozymes with their target mRNAs. Genome 40, 785ā797.
Cochet, O., Kenigsberg, M., Delumeau, I., Duchesne, M., Schweighoffer, F., Tocque, B., and Teillaud, J. L. (1998) Intracellular expression and functional properties of an anti-p21Ras scFv derived from a rat hybridoma containing specific lambda and irrelevant kappa light chains. Mol. Immunol. 35, 1097ā1110.
Cochet, O., Kenigsberg, M., Delumeau, I., Virone-Oddos, A., Multon, M. C., Fridman, W. H., et al. (1998) Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 58, 1170ā1176.
Jannot, C. B., Beerli, R. R., Mason, S., Gullick, W. J., and Hynes, N. E. (1996) Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 13, 275ā282.
Roth, J. A. (1996) Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Human Gene Ther. 7, 875ā889.
Zhang, Y., Nemunaitis, J., Scanlon, K. J., and Tong, A. W. (2000) Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Ther. 7, 2041ā2050.
Zhang, Y. A., Nemunaitis, J., and Tong, A. W. (2000) Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells. Mol. Biotechnol. 15, 39ā49.
Nemunaitis, J., Holmlund, J. T., Kraynak, M., Richards, D., Bruce, J., Ognoskie, N., et al. (1999) Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. 17, 3586ā3595.
Cunningham, C. C., Holmlund, J. T., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A., and Nemunaitis, J. (2000) A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 6, 1626ā1631.
Fuchs, E. J., Bedi, A., Jones, R. J., and Hess, A. D. (1995) Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res. 55, 463ā466.
Shtil, A. A., Turner, J. G., Durfee, J., Dalton, W. S., and Yu, H. (1999) Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. Blood 93, 1831ā1837.
Boon, T. and van der Bruggen, P. (1996) Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725ā729.
Boon, T. and Old, L. J. (1997) Cancer tumor antigens. Curr. Opin. Immunol. 9, 681ā683.
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643ā1647.
Pieper, R., Christian, R. E., Gonzales, M. I., Nishimura, M. I., Gupta, G., Settlage, R. E., et al. (1999) Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells [see comments]. J. Exp. Med. 189, 757ā766.
Wang, R. F., Wang, X., Atwood, A. C., Topalian, S. L., and Rosenberg, S. A. (1999) Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284, 1351ā1354.
Pardoll, D. M., Golumbek, P., Levitsky, H., and Jaffee, L. (1992) Molecular engineering of the antitumor immune response. Bone Marrow Transplant. 9, 182ā186.
Leach, D. R., Krummel, M. F., and Allison, J. P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade [see comments]. Science 271, 1734ā1736.
Vincent, R. G., Chu, T. M., Lane, W. W., Gutierrez, A. C., Stegemann, P. J., and Madajewicz, S. (1978) Carcinoembryonic antigen as a monitor of successful surgical resection in 130 patients with carcinoma of the lung. J. Thorac. Cardiovasc. Surg. 75, 734ā739.
Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J., and Schlom, J. (1992) Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine [see comments]. J. Natl. Cancer Inst. 84, 1084ā1091.
Kantor, J., Irvine, K., Abrams, S., Snoy, P., Olsen, R., Greiner, J., et al. (1992) Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 52, 6917ā6925.
Cole, D. J., Wilson, M. C., Baron, P. L., OāBrien, P., Reed, C., Tsang, K. Y., and Schlom, J. (1996) Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Human Gene Ther. 7, 1381ā1394.
Dickler, M. N., Ragupathi, G., Liu, N. X., Musselli, C., Martino, D. J., Miller, V. A., et al. (1999) Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res. 5, 2773ā2779.
Lee, L., Wang, R. F., Wang, X., Mixon, A., Johnson, B. E., Rosenberg, S. A., and Schrump, D. S. (1999) NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J. Sci. Am. 5, 20ā25.
Rowse, G. J., Tempero, R. M., VanLith, M. L., Hollingsworth, M. A., and Gendler, S. J. (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58, 315ā321.
Pardoll, D. M. (1993) Genetically engineered tumor vaccines. Ann. NY Acad. Sci. 690, 301ā310.
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539ā3543.
Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961ā965.
Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., et al. (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537ā1546.
Sanda, M. G., Ayyagari, S. R., Jaffee, E. M., Epstein, J. I., Clift, S. L., Cohen, L. K., et al. (1994) Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151, 622ā628.
Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M., et al. (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160ā5168.
Jaffee, E. M., et el. (2001) Novel Allogeneic Granulocyte-Macrophase Colony-stimulating factor-secreting tumor vaccine for Pancreatic Cancer: A Phase I trial of safety and immune activation. J. Clin. Oncol. 19(1), 145ā156.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Haura, E.B., Sotomayor, E., Antonia, S.J. (2003). Gene Therapy for Lung Cancer. In: Driscoll, B. (eds) Lung Cancer. Methods in Molecular Medicineā¢, vol 75. Humana Press, Totowa, NJ. https://doi.org/10.1385/1-59259-324-0:529
Download citation
DOI: https://doi.org/10.1385/1-59259-324-0:529
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-0-89603-920-9
Online ISBN: 978-1-59259-324-8
eBook Packages: Springer Protocols